A NOVEL multicomponent vaccine combining seasonal influenza and COVID-19 antigens has shown promising safety and immune responses in adults, according to a recent phase 1/2 clinical trial.
Multicomponent Vaccine Offers Dual Protection
Childhood and adult respiratory illnesses caused by influenza and COVID-19 contribute significantly to global morbidity and mortality, highlighting the need for more efficient vaccination strategies. The vaccine, known as mRNA-1073, combines antigens from previously authorised mRNA-based influenza and COVID-19 vaccines into a single dose, potentially simplifying immunisation schedules.
Study Design and Safety Profile
The trial enrolled 550 healthy adults aged 18 to 75 years, randomly assigned to receive varying doses of mRNA-1073, individual vaccines, or a combination of the two mRNA vaccines. Participants were monitored for safety, tolerability, and immune responses over 6 months. The study found that most side effects were mild or moderate, with no severe vaccine-related events or deaths reported. Reactogenicity increased with dose but remained within acceptable limits, supporting the vaccine’s safety in adults.
Robust and Durable Immune Response
Immunogenicity analysis demonstrated that a single dose of mRNA-1073 elicited strong and durable antibody responses against all influenza and COVID-19 strains matched to the vaccine. Systems serology profiling revealed balanced immune responses comparable to those observed when the influenza and COVID-19 vaccines were administered together, indicating that the combined vaccine does not compromise immune efficacy. Antibody responses persisted through six months, suggesting long-term protection from both pathogens.
Implications for Vaccination Strategies
The development of a single-dose, multicomponent mRNA vaccine could streamline vaccination campaigns and increase uptake by reducing the need for multiple injections. Such vaccines may be particularly beneficial for older adults or populations with limited access to healthcare. While further studies are required to confirm efficacy and long-term protection in larger, diverse populations, the findings support ongoing research into mRNA-based vaccines that simultaneously target multiple respiratory pathogens.
Reference
Rudman Spergel AK et al. Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults. Hum Vaccin Immunother. 2026;22(1):2589644.
